Patricia Inácio, PhD, science writer —

Researchers at Yale School of Medicine will use a $9 million grant to generate a detailed map of the “gut-brain axis,” the complex communication route between brain and belly — focusing on the gut microbiome — that is increasingly thought to play a key role in Parkinson’s and other…

An older age at diagnosis, but also reduced physical activity due to medical or social conditions, were significantly linked with faster motor decline in people with  Parkinson’s disease, a Japanese study has found. According to its authors, maintaining daily physical activity and allowing patients to move freely is paramount…

Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

The accumulation of toxic clumps of the protein TDP-43 — rather than alpha-synuclein protein, considered the hallmark of Parkinson’s disease — likely was the cause of death of nerve cells in a 60-year-old Japanese man diagnosed with the neurodegenerative disease, a case report shows. The findings suggest the need…

Labcorp has launched a test to detect the presence of a protein called neurofilament light chain (NfL) in the blood, a sign of nerve cell damage and death. The test will aid neurologists in the diagnosis of Parkinson’s and other neurodegenerative diseases, according to the company’s press…

A $500,000 grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to EpicentRx will support continuing work into the neuroprotective effects of RRx-001, its lead small molecule treatment for Parkinson’s disease. RRx-001 works by blocking the activation of the NLRP3 inflammasome, known to play a key role in promoting…

PharmaTher has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering use of the painkiller ketamine for the treatment of Parkinson’s disease and motor disorders that cause uncontrolled, involuntary movements. A Notice of Allowance means the USPTO has decided to issue the…

EVER Pharma has launched a mobile app for the D-mine Pump, its portable micro-infusion pump designed to continuously deliver apomorphine under the skin (subcutaneously) to patients with Parkinson’s disease. The app was designed to train healthcare professionals and caregivers on how to use the pump and program the infusion device. It’s…

Exposure to high concentrations of copper accelerates the formation of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease, a study shows. The study, “Single-Particle Resolution of Copper-Associated Annular α‑Synuclein Oligomers Reveals Potential Therapeutic Targets of Neurodegeneration,” was published in the journal…

Annovis Bio has been given the go-ahead by the U.S. Food and Drug Administration (FDA) to begin a Phase 3 clinical trial to test buntanetap (ANVS401) as an oral therapy for early-stage Parkinson’s disease. “With this FDA notice in hand, we are thrilled to…